Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

Gilead Sciences’ Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets) has been approved by the ...

Biktarvy is the first and only INSTI-Based Single-Tablet regimen that is FDA approved and DHHS Guideline Recommended for people who are virologically suppressed with M184V/I resistance.

Gilead's Q2 earnings beat and raised 2025 outlook lift shares 7.3%, fueled by HIV gains, Trodelvy strength, and new PrEP ...

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are ...

Biktarvy, Gilead's latest triple therapy, was approved by the FDA in February 2018 as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history ...

Biktarvy is currently lining Gilead’s pockets as the company’s top-selling drug. For the first three months of 2022, Biktarvy pulled down sales of $2.15 billion worldwide.

Results showed that after switching to Biktarvy, 100% of patients 6 to <12 years of age and 98% of patients 12 to <18 years of age remained virologically suppressed (HIV-1 RNA <50 copies/mL).

Biktarvy is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral (ARV) treatment history or to ...

Biktarvy sales jumped 18% from 2021's first quarter to $2.15 billion, while Descovy revenues increased 4% to $374 million. On the flip side, Truvada sales took an expected hit, plummeting 72% ...

Biktarvy - Drug Insight, 2019 report provides comprehensive information of the drug, Biktarvy. It includes drugs overview, Biktarvy mechanism of action, clinical trials, regulatory milestones ...